{"id":"W4417526956","doi":"10.1016/j.cllc.2025.12.005","title":"Patient-Relevant Outcomes From the Phase III MARIPOSA-2 Trial: Amivantamab-Chemotherapy Versus Chemotherapy in EGFR-Mutant Advanced Non-Small-Cell Lung Cancer Following Disease Progression on Osimertinib","year":2025,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Alberta Cancer Foundation","funders":"Janssen Research and Development; Johnson and Johnson","keywords":"Chemotherapy; Lung cancer; Osimertinib; Phases of clinical research; Pemetrexed; Disease; Adenocarcinoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003127819,0.0005431957,0.001091395,0.0001173971,0.0002522109,0.00006467797,0.0002966022,0.0002337037,0.0004283606],"category_scores_gemma":[0.0002823697,0.0003437257,0.0007099222,0.0004803576,0.000111604,0.0001229957,0.00007726947,0.0006449127,0.000006056148],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001013817,"about_ca_system_score_gemma":0.00168319,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006885766,"about_ca_topic_score_gemma":0.0002834872,"domain_scores_codex":[0.9963021,0.000187679,0.00134097,0.001030881,0.0005179916,0.0006203494],"domain_scores_gemma":[0.9966676,0.001473319,0.0004391813,0.0009029069,0.0001120662,0.0004049395],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.2398966,0.006312909,0.3987968,0.0001651349,0.003329328,0.0001620473,0.001232715,0.0001488837,0.000660128,0.00003350301,0.007187,0.342075],"study_design_scores_gemma":[0.8092586,0.002945868,0.1460346,0.006042033,0.005356152,2.4294e-7,0.0005252308,0.007118514,0.002707752,0.0001238117,0.01892411,0.000963131],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9621586,0.00964982,0.00008064175,0.01507809,0.005678899,0.00615945,0.0002027215,0.0001178666,0.0008738908],"genre_scores_gemma":[0.9788879,0.004407803,0.0003180017,0.01195109,0.0004650042,0.002553245,0.0001518556,0.0001010335,0.00116413],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.569362,"threshold_uncertainty_score":0.9999015,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02508663360335096,"score_gpt":0.4423766151278952,"score_spread":0.4172899815245443,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}